AXERT
LOE ApproachingNDAORALTABLET
Approved
May 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
AXERT by Johnson & Johnson is 5-ht 1d , 5-ht 1b , and 5-ht 1f receptors. Approved for cluster headache () 1. First approved in 2001.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AXERT (almotriptan) is an oral small-molecule triptan approved in 2001 for acute treatment of cluster headache. It works by selective agonism at 5-HT1D, 5-HT1B, and 5-HT1F serotonin receptors, with minimal off-target binding across adrenergic, dopamine, and other receptor families. The mechanism enables rapid symptom relief in a patient population with severe, episodic headache attacks.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), indicating a mature team focused on defense and retention rather than expansion.
Mechanism of Action
5-HT 1D , 5-HT 1B , and 5-HT 1F receptors. Almotriptan has weak affinity for 5-HT 1A and 5-HT 7 receptors, but has no significant affinity or pharmacological activity at 5-HT 2 , 5-HT 3 , 5-HT 4 , 5-HT 6 ; alpha or beta adrenergic; adenosine (A 1 , A 2 ); angiotensin (AT 1 , AT 2 ); dopamine (D 1 ,…
Indications (1)
Clinical Trials (2)
Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine
Started Jun 2005
406 enrolled
MigraineClassic MigraineCommon Migraine
A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents
Started Jul 2003
866 enrolled
Migraine
Worked on AXERT at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.